Loading...

Phio Pharmaceuticals Corp.

PHIOW•NASDAQ
Healthcare
Biotechnology
$0.02
$0.006(36.47%)

Phio Pharmaceuticals Corp. (PHIOW) Stock Overview

Explore Phio Pharmaceuticals Corp.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.5/100

Key Financials

Market Cap421.4K
P/E Ratio-13.85
EPS (TTM)$-1.13
ROE-1.06%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

PHIOW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Phio Pharmaceuticals Corp. (PHIOW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -13.85 and a market capitalization of 421.4K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for PHIOWStats details for PHIOW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PHIOWAnalyst Recommendations details for PHIOW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

CEO

Gerrit Dispersyn Med. Sc

Employees

10

Headquarters

257 Simarano Drive, Marlborough, MA

Founded

2022

Frequently Asked Questions

;